Dana Farber Cancer Institute
Jennifer Ligibel, MD, is a medical oncologist in the Women’s Cancer Program at Dana-Farber Cancer Institute with a research interest in the impact of lifestyle factors, such as physical activity and body weight, upon cancer risk and outcomes. She has conducted a number of lifestyle intervention trials in cancer populations, looking at endpoints such as biomarkers associated with cancer risk and outcomes, fitness, body composition measures, as well as quality of life measures. Dr. Ligibel has also conducted numerous multicenter exercise and weight loss studies conducted through NCI Cooperative Groups such as the Cancer and Leukemia Group B Prevention and Alliance. Ongoing studies include: a multicenter Window of Opportunity study looking at the impact of exercise upon biomarkers in malignant breast tissue; a multicenter trial conducted through the Translational Breast Cancer Research Consortium evaluating the impact of novel treatments, including dietary weight loss +/- exercise, upon cancer outcomes and inflammatory and metabolic hormones in individuals with locally advanced breast cancer; and multicenter lifestyle intervention study through the Harvard Transdisciplinary Research in Energetics and Cancer (TREC) award looking at the impact of physical activity and/or metformin upon metabolic biomarkers in colorectal and breast cancer survivors. Dr. Ligibel has mentored numerous early career investigators as well as medical residents, fellows and clinicians, and adds depth and breadth as a clinical oncologist researcher to our Senior Advisory Board and TREC Training Workshop faculty.